Ca²⁺ signaling responses for STL agonist compounds 11–14.

<p>The top four panels (<b>A–D</b>) display traces from a single experiment of average individual cell [Ca²⁺]_i (± SEM) over time for 16HBE14o-cells exposed to PAR₂ STL agonist compounds <b>11–14</b>. <b>(E)</b> Concentrations (Compound <b>11</b>: 2at-Cha-IGR-<i>PEG</i>₂-<i>Hdc</i>, 200 nM; <b>12</b>: 5io-Cha-IGR-<i>PEG</i>₂-<i>Hdc</i>, 50 nM; <b>13</b>: 2at-Cha-I-<i>PEG</i>₂-<i>Hdc</i>, 600 nM; <b>14</b>: 5io-Cha-I-<i>PEG</i>₂-<i>Hdc</i>, 300 nM) were chosen to reflect minimal agonist concentration necessary to result in the maximal activation of 16HBE14o- cells (n≥3 for each compound). (<b>F</b>) Compounds <b>11</b>, <b>13</b> and <b>14</b> all demonstrated significantly delayed responses to Ca²⁺ peak and (<b>G</b>) compounds <b>13</b> and <b>14</b> also displayed significantly reduced peak [Ca²⁺]_i changes. Of this group, only compound <b>12</b> displayed Ca²⁺ signaling responses representative of full PAR₂ agonism.